OKYO Pharma (NASDAQ:OKYO) Stock Rating Reaffirmed by HC Wainwright

OKYO Pharma (NASDAQ:OKYO)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 469.11% from the company’s previous close. HC Wainwright also issued estimates for OKYO Pharma’s Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.40) EPS.

OKYO Pharma Stock Performance

OKYO Pharma stock opened at $1.23 on Thursday. OKYO Pharma has a 12 month low of $0.81 and a 12 month high of $2.12. The stock’s 50-day moving average is $1.04 and its 200-day moving average is $1.24.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.